Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced three new patent awards. In the European Union, the company received a new patent in Lexaria’s patent family #6: Transdermal and/or Dermal Delivery of Lipophilic Active Agents. Following an earlier one granted in Canada, this is the company’s second patent in this family. In Canada, Lexaria has received a new patent in patent family #18: Compositions and Methods for Enhanced Delivery of Antiviral Agents. This is the company’s fourth granted patent in this family, which was previously granted in the U.S., Australia and Japan. Further, building on prior patent success in the U.S. related to epilepsy, Lexaria has received its fourth U.S. patent in patent family #24, Compositions and Methods for Treating Epilepsy. The patent complements earlier research that discovered DehydraTECH-CBD was capable of mitigating epileptic seizures in rodents and was also absorbed into the bloodstream more effectively than the commercially available cannabinoid-based anti-seizure medication.

To view the full press release, visit https://cnw.fm/ZDAYZ

About Lexaria Bioscience Corp.

DehydraTECH(TM) is Lexaria’s patented drug delivery formulation and processing platform technology that improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 46 patents granted and many patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CanadianCannabisWire

CanadianCannabisWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the Canadian cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CanadianCannabisWire, text “CCWIRE” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CanadianCannabisWire.com

Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: www.CanadianCannabisWire.com/Disclaimer

CanadianCannabisWire
Toronto, ON
www.CanadianCannabisWire.com
905.674.5977 Office
Editor@CanadianCannabisWire.com

CanadianCannabisWire is powered by IBN